<DOC>
	<DOCNO>NCT00240331</DOCNO>
	<brief_summary>The purpose study see rosuvastatin help reduce number heart attack , stroke cardiovascular death patient undergoing haemodialysis .</brief_summary>
	<brief_title>AURORA : Crestor 10mg Versus Placebo Subjects With End-stage Renal Disease ( ESRD )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male female subject endstage renal failure age 5080 year , receive regular haemodialysis treatment least 3 month Subjects underlying condition expect limit survival less 1 year also unrelated endstage renal disease ( ESRD ) . Subjects receive statin therapy within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>End Stage Renal Failure</keyword>
</DOC>